management and treatment of asthma. colombia
TRANSCRIPT
Maria Bea Merscher – Interna en Medicina Interna – Estudiante de Intercambio
GINA – Management and Treatment of Asthma
Publish guidelines
What is GINA?
How does GINA define asthma?
“Asthma is a chronic inflammatory disorder of the airways in which many cells
and cellular elements play a role. The chronic inflammation is associated with
airway hyperresponsiveness that leads to recurrent episodes of wheezing,
breathlessness, chest tightness and coughing particularly at night or in the
early morning. These episodes are usually associated with widespread, but
variable airflow obstruction within the lung that is often reversible either
spontaneously or with treatment.”
What is the aim of GINA?
Guided self-management (1A)
What is the aim of GINA?
Improve
the
Improve
the
patient’s
patient’s
compliance!
!
compliance!
!
Don’t forge
t the
Don’t forge
t the
education of o
thers!
education of o
thers!
Levels of Control Characteristics
Controlled (all of the following)
Partially controlled Not controlled
Daily symptoms No (≤ 2x per week) >2 per week
≥3 characteristics of partially controlled asthma in any week
Limitation of activities
No Any
Nighttime symptoms / patient
is woken by symptoms
No Any
Use of short-acting β2-agonists for
symptom control
No (≤ 2x per week) >2 per week
Pulmonary function (FEV1 or peak flow)
>80% predicted/personal
best
<80% predicted/personal
best
Exacerbations No ≥1 1x per week
Impairment
Risk
Severity
Severity Frequency of
symptomsNighttime symptoms
FEV1Variety of
FEV1
Usage of short-acting β2-agonists
Intermittent ≤ 2x per week≤ 2x per month
≥ 80% < 20%≤ 2 days per
week
Mild persistent
> 2x per week but not daily
3-4 x per month
≥ 80% 20-30%> 2 days per
week but not daily
Moderate persistent
Daily > 1x per week
but not at nighttime
60-80% > 30% Daily
Severe persistent
Throughout the day
Frequent (~7x per week)
< 60% > 30%Several times
a day
Controllers vs Relievers
Management Based on Control
Management Based on Control
Routes of Administration
Inhaled Glucocorticosteroids
Equipotency of Inhaled Glucocorticosteroids
Side effects: Inhaled Glucocorticosteroids
Leukotriene Modifiers
Side effects: Leukotriene Modifiers
Long-acting inhaled β2-agonists
Long-acting inhaled β2-agonists
Theophylline
Theophylline
Theophylline• Xanthin derivative• Competitive nonselective phosphodiesterase inhibitor raises
intracellular cAMP activates PKA inhibits TNF-alpha and inhibits leukotriene synthesis reduces inflammation and innate immunity
• Nonselective adenosine receptor antagonist, antagonizing A1, A2, A3 receptors almost equally explains cardiac side effects
• Inhibits TGF (transforming growth factor)-beta-mediated conversion of pulmonary fibroblasts into myofibroblasts in COPD and asthma via cAMP-PKA pathway which codes for collagen
• Directly activates HDAC2 (histone deacetylase) repackaging of DNA promoter regions of inflammatory genes are unavailable for binding of transcription factors such as NF-kappa-B
• Smoking inhibits the HDAC2-activity theophylline should be considered in smoking asthmatics
Systemic glucocorticosteroids
Systemic glucocorticosteroids
Patients with long-term systemic glucocorticosteroids should receive osteoporosis-profilaxis!
Systemic glucocorticosteroids and osteoporosis
Anti-IgE
Anti-IgE
Severity of Asthma Exacerbations
Rapid-acting inhaled β2-agonists
Rapid-acting inhaled β2-agonists
Systemic glucocorticosteroids
Systemic glucocorticosteroids
Anticholinergics
Anticholinergics
Theophylline
Short-acting oral β2-agonists